Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Caladrius Biosciences Inc, Medical Devices Deals, 2012 to YTD 2018 12
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 15
Partnerships 15
Kiadis Pharma Enters into Agreement with PCT 15
Caladrius Biosciences Enters into Development Agreement with Sanford Research 16
Caladrius Biosciences Enters into Research Agreement with University of Southern California and California Institute of Technology 17
NeoStem Enters into Research Agreement with Massachusetts Eye and Ear Infirmar and Schepens Eye Research Institute 18
NeoStem Enters Into Agreement With University of California, San Francisco To Develop Human Regulatory T Cells 19
Licensing Agreements 21
Caladrius Biosciences Enters into Licensing Agreement with Shire 21
Caladrius Biosciences Enters into Licensing Agreement with AiVita Biomedical 22
Hitachi Chemical Enters into Licensing Agreement with Progenitor Cell Therapy 23
AiVita Biomedical Enters into Licensing Agreement with Caladrius Biosciences 24
SPS Cardio Enters into Licensing Agreement with Caladrius Biosciences 25
NeoStem Enters into Licensing Agreement with Rockefeller University for Patented Technologies 26
NeoStem Enters Into Licensing Agreement With Cellular Biomedicine 27
NeoStem Enters Into Licensing Agreement With University of California, San Francisco 29
Equity Offering 30
Caladrius Biosciences Plans to Raise up to USD25 Million in Public Offering of Shares 30
Caladrius Biosciences Plans to Raise USD3.8 Million in Private Placement of Shares 31
Caladrius Biosciences Raises USD6.6 Million in Private Placement of Shares 33
Caladrius Biosciences to Raise USD4 Million in Private Placement of Shares 35
Caladrius Biosciences Plans to Raise Funds through Public offering of Shares 37
Caladrius Biosciences Raises USD1 Million in Private Placement of Shares 38
NeoStem Raises USD29 Million in Public Offering of Shares 39
NeoStem to Raise USD30 Million in Private Placement of Shares 40
NeoStem Completes Public Offering Of Shares For US$40.25 Million 41
NeoStem Files Registration Statement For Private Placement Of Shares For US$8 Million 42
NeoStem Completes Public Offering Of Shares For US$11.5 Million 43
NeoStem Completes Private Placement Of Common Stock For US$3 Million 44
NeoStem Completes Public Offering Of Units For US$6.8 Million 46
Acquisition 48
Hitachi Chemical Acquires Remaining 80.1% Interest in Progenitor Cell Therapy from Caladrius Biosciences 48
Caladrius Biosciences Sells 20% Stake in Progenitor Cell Therapy to Hitachi Chemical for USD19.4 Million 50
NeoStem Completes Acquisition Of California Stem Cell 51
NeoStem Completes Sale Of 51% Stake In Suzhou Erye Pharma For US$12 Million 53
Caladrius Biosciences Inc – Key Competitors 54
Caladrius Biosciences Inc – Key Employees 55
Caladrius Biosciences Inc – Locations And Subsidiaries 56
Head Office 56
Other Locations & Subsidiaries 56
Recent Developments 57
Financial Announcements 57
Aug 09, 2018: Caladrius Biosciences reports 2018 second quarter and first six months financial results 57
May 10, 2018: Caladrius Biosciences Reports 2018 First Quarter Financial Results 59
Mar 22, 2018: Caladrius Biosciences Reports 2017 Fourth Quarter and Year End Financial Results 60
Nov 09, 2017: Caladrius Biosciences Reports 2017 Third Quarter Results 62
Aug 10, 2017: Caladrius Biosciences Reports 2017 Second Quarter Results 64
May 15, 2017: Caladrius Biosciences Announces 2017 First Quarter Financial Results 66
Mar 17, 2017: Caladrius Biosciences Announces 2016 Fourth Quarter and Full Year Financial Results 68
Other Significant Developments 70
Jul 02, 2018: Dr. Marilyn Glassberg Presents Findings on Stem Cell Treatments for Lung Diseases 70
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Caladrius Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 10
Caladrius Biosciences Inc, Medical Devices Deals, 2012 to YTD 2018 12
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Kiadis Pharma Enters into Agreement with PCT 15
Caladrius Biosciences Enters into Development Agreement with Sanford Research 16
Caladrius Biosciences Enters into Research Agreement with University of Southern California and California Institute of Technology 17
NeoStem Enters into Research Agreement with Massachusetts Eye and Ear Infirmar and Schepens Eye Research Institute 18
NeoStem Enters Into Agreement With University of California, San Francisco To Develop Human Regulatory T Cells 19
Caladrius Biosciences Enters into Licensing Agreement with Shire 21
Caladrius Biosciences Enters into Licensing Agreement with AiVita Biomedical 22
Hitachi Chemical Enters into Licensing Agreement with Progenitor Cell Therapy 23
AiVita Biomedical Enters into Licensing Agreement with Caladrius Biosciences 24
SPS Cardio Enters into Licensing Agreement with Caladrius Biosciences 25
NeoStem Enters into Licensing Agreement with Rockefeller University for Patented Technologies 26
NeoStem Enters Into Licensing Agreement With Cellular Biomedicine 27
NeoStem Enters Into Licensing Agreement With University of California, San Francisco 29
Caladrius Biosciences Plans to Raise up to USD25 Million in Public Offering of Shares 30
Caladrius Biosciences Plans to Raise USD3.8 Million in Private Placement of Shares 31
Caladrius Biosciences Raises USD6.6 Million in Private Placement of Shares 33
Caladrius Biosciences to Raise USD4 Million in Private Placement of Shares 35
Caladrius Biosciences Plans to Raise Funds through Public offering of Shares 37
Caladrius Biosciences Raises USD1 Million in Private Placement of Shares 38
NeoStem Raises USD29 Million in Public Offering of Shares 39
NeoStem to Raise USD30 Million in Private Placement of Shares 40
NeoStem Completes Public Offering Of Shares For US$40.25 Million 41
NeoStem Files Registration Statement For Private Placement Of Shares For US$8 Million 42
NeoStem Completes Public Offering Of Shares For US$11.5 Million 43
NeoStem Completes Private Placement Of Common Stock For US$3 Million 44
NeoStem Completes Public Offering Of Units For US$6.8 Million 46
Hitachi Chemical Acquires Remaining 80.1% Interest in Progenitor Cell Therapy from Caladrius Biosciences 48
Caladrius Biosciences Sells 20% Stake in Progenitor Cell Therapy to Hitachi Chemical for USD19.4 Million 50
NeoStem Completes Acquisition Of California Stem Cell 51
NeoStem Completes Sale Of 51% Stake In Suzhou Erye Pharma For US$12 Million 53
Caladrius Biosciences Inc, Key Competitors 54
Caladrius Biosciences Inc, Key Employees 55
Caladrius Biosciences Inc, Other Locations 56
Caladrius Biosciences Inc, Subsidiaries 56
List of Figures
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Caladrius Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Caladrius Biosciences Inc, Medical Devices Deals, 2012 to YTD 2018 12